SmartTRAK talks with Raoul Verheggen, Global Product Director for DSM Biomedical, regarding the Company’s recent foray into the wound care space and how its addressing unmet needs for patients and businesses

Novel materials and components are key to innovative wound care products that provide superior patient outcomes. DSM Biomedical is a B2B supplier whose business it is to provide these unique components to the medical device industry. SmartTRAK talks with Raoul Verheggen of DSM Biomedical, Global Product Director for Wound, about the company, their capabilities and plans moving forward in support of wound care. A transcript of the interview is below. To listen to the interview recorded via Uberconference, click on the following video. 

SmartTRAK highlights the latest research on Sigvaris SECURE presented at SAWC Fall

A novel hybrid compression garment offers promise for patients with difficult-to-treat chronic edema according to an 11-patient case series presented at SAWC Fall. Patients with chronic edema, including lymphedema, are challenged in finding compression garments that are clinically efficacious, cosmetically appealing and comfortable to wear. The 11-patient case series evaluated Sigvaris’ recently launched SECURE, an innovative new Compression and Containment Hybrid (CCH) garment that combines the comfort of circular knit garments and the stiffness traditionally provided by thicker textiles, inelastic wraps or flat knit garments. The new hybrid circular knit garments are thin, cosmetically appealing, and meet the clinical requirement of chronic edema management – graduated compression and containment.

Dressings recover Q418, all segments showing solid gains

For FY18, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics were up +4.1% YoY. Acelity remains the global market leader followed by S&N and Mölnlycke. Advanced Dressings, the workhorse of Advanced Wound Care, accounts for 52.3% of WW revenues, up +3.3% YoY. Skin/Dermal Substitute (CTP) revenue was up +10.7% YoY, lower than previous years, but still double-digit gains. WW NPWT was up +4.3% YoY, with traditional devices having a slight uptick and single-use driving the increase of +28.9%.

Among the many topics covered in the Q418/FY18 Advanced Wound Care Market Recap are:

S&N plans to shore up its Advanced Wound Bioactives business with the acquisition of Osiris Therapeutics but the deal may be in question as Osiris shareholders challenge the price.

 Smith & Nephew (S&N) announced on March 12, 2019 that it has agreed to acquire Osiris Therapeutics for $660MM with the deal expected to close Q219. However, the deal could be in question as a group of Osiris shareholders is suing to block the acquisition. The lawsuit disputes Cantor Fitzgerald’s discounted cash flow analysis, saying it does not adequately reflect Osiris’s future growth prospects, and is based on growth rates that are about half of what Osiris has experienced in recent years, resulting in a valuation that is too low. The acquisition would add the Osiris’s Grafix and Stravix product lines to S&N’s ailing Advanced Wound Bioactives portfolio. If allowed to proceed, the acquisition would solidify S&N’s leadership in wound biologics and changes the competitive landscape in the Advanced Wound Care market.

SmartTRAK was cited as a source in a press release from Smith & Nephew entitled "Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc."

FY18 showed solid gains in all segments, up +5.7% YoY, as antimicrobial devices take the lead.

Following the last fall's Advanced Wound Care meeting, SmartTRAK's Susan Paquette, VP Wound, reported on advances in negative pressure wound therapy (NPWT), fiber dressings and human dermal tissue and the latest research and company news, identifying what’s new and what’s next in the market for advanced wound care.

Growth continues for another quarter as market leaders gain more share.

For Q318, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access Adjunct Products market grew +4.3% YoY.

Among the many topics covered in the Q318 Infection Prevention Market Recap are:

All segments showing softness, lowest quarterly growth rate since 2015

For Q318, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics was up +3.0% YoY, with Acelity, also known as KCI, maintaining its leadership position with estimated Q318 revenues of...

Products that prevent peripheral IV failures could be the next big thing in the market for vascular access adjunct products, a market opportunity valued at more than $600MM in the US alone, according to SmartTRAK estimates.

All eyes were on the high failure rate of peripheral IVs at the Association of Vascular Access (AVA) 2018 Annual Scientific Meeting, with speakers highlighting the 2015 article by Helm et al. “Accepted but Unacceptable: Peripheral IV Catheter Failure,” which estimates a PIV failure rate of 35% to 50% primarily caused by phlebitis, infiltration, occlusion/mechanical failure, dislodgment and infection. Failure is defined as the removal of the catheter prior to the end of its intended life or before the 72 to 96 hours previously used as a guideline. And with up to 90% of all hospitalized patients receiving a PIV, it is a standard but often overlooked procedure in the hospital.

The primary emphasis over the last 10 to 15 years has been the reduction of catheter-related bloodstream infections (CRBSIs) associated with central line catheters. Driving this focus has been CMS reimbursement penalties for hospital acquired central line bloodstream infections (CLABSIs). This new focus on PIVs could be exciting for manufacturers, especially those with adjunct vascular access products. Clinicians insert approximately 250 million PIVs every year in the US (assuming a 25% failure rate on first insertion), a market that is 25 times larger than the US market for central line catheters...